Dry mouth;Mundtrockenheit: Ursachen und therapiemöglichkeiten

Medizinische Monatsschrift fur Pharmazeuten

Volumn 29, Issue 4, 2006, Pages 129-136

  Reiß, Michael ^a,b   Reiß, Gilfe ^a,c  

^a HNO Abteilung ^*

^b Elblandkliniken Radebeul   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; ATROPINE; BECLOMETASONE; CAPTOPRIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE; DEXCHLORPHENIRAMINE; DIMETINDENE; DIPHENHYDRAMINE; DOXYLAMINE; ENALAPRIL; FLUTICASONE; GLUCOCORTICOID; IBUPROFEN; MECLOZINE; MOCLOBEMIDE; NAPROXEN; NEUROLEPTIC AGENT; OXYBUTYNIN; PIRENZEPINE; PIROXICAM; REBOXETINE; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE; UNINDEXED DRUG; VALDECOXIB;

CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; HEAD AND NECK TUMOR; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; SALIVATION; SARCOIDOSIS; SJOEGREN SYNDROME; XEROSTOMIA;

EID: 33645930350     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Anaya JM, Ogawa N, Talal N. Sjogren's syndrome in childhood. J Rheumatol 1995;22:1152-8.
2. Arisawa H, Fukui K, Fujise N, Masunaga H. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren's syndrome, 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle. Arzneimittelforschung 2002;52:81-8.
3. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am 2005;49:309-26.
4. . Bassichis BA, Marple BF. Dry mouth and nose in the older patient. What every PCP should know. Geriatrics 2002;57:22-4, 9, 32.
5. . Bruce SD. Radiation-induced xerostomia: how dry is your patient? Clin J Oncol Nurs 2004;8:61-7.
6. Brunstrom JM. Effects of mouth dryness on drinking behavior and beverage acceptability. Physiol Behav 2002;76:423-9.
7. Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology 2003;20:64-77.
8. Chambers MS. Sjogren's syndrome. ORL Head Neck Nurs 2004;22: 22-30, quiz 2-3.
9. Chilla R. Klinik, Diagnostik und Therapie der Xerostomie. Versuch einer Betrachtung unter pathophysiologischen Gesichtspunkten. HNO 1982;30:201-7.
10. Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med 2000;14:197-203.
11. Davies AN, Daniels C, Pugh R, Sharma K. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med 1998;12:105-11.
12. du Toit DF, Nortje C. Salivary glands: applied anatomy and clinical correlates. Sadj 2004;59:65-6, 9-71, 3-4.
13. Dunst J, Semlin S, Pigorsch S, Muller AC, et al. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol 2000;176:416-21.
14. Exposito-Delgado AJ, Vallejo-Bolanos E, Martos-Cobo EG. Oral manifestations of HIV infection in infants: a review article. Med Oral Patol Oral Cir Bucal 2004;9:415-20, 410-5.
15. Fox PC. Salivary enhancement therapies. Caries Res 2004;38:241-6.
16. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current status and new directions. Oncology 2002;63(Suppl 2):2-10.
17. Greenspan D. Xerostomia: diagnosis and management. Oncology (Huntingt) 1996;10:7-11.
18. Jenkins GN. The physiology and biochemistry of the mouth. Oxford: Blackwell, 1978.
19. Jha N, Seikaly H, McGaw T, Coulter L. Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 2000;46:7-11.
20. Mattson JS, Cerutis DR. Diabetes mellitus: a review of the literature and dental implications. Compend Contin Educ Dent 2001;22:757-60, 62, 64 passim; quiz 73.
21. Meurman JH, Laine P, Keinanen S, Pyrhonen S, et al. Five-year follow-up of saliva in patients treated for lymphomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:447-52.
22. Meyer-Lueckel H, Kielbassa AM. Die Verwendung von Speichelersatzmitteln bei Patienten mit Xerostomie. Schweiz Monatsschr Zahnmed 2002;112:1037-58.
23. Meyer-Lueckel H, Schulte-Monting J, Kielbassa AM. The effect of commercially available saliva substitutes on predemineralized bovine dentin in vitro. Oral Dis 2002;8:192-8.
24. Muhl C, Fox JM. Antiparkinsonmittel und Antihypertensiva. In: Fox JM, Jörg J (eds.). Neurologische Pharmakotherapie. Stuttgart - New York: Thieme, 2004:5-55.
25. Nagler RM, Hershkovich O. Sialochemical and gustatory analysis in patients with oral sensory complaints. J Pain 2004;5:56-63.
26. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 1999;15:103-16.
27. Navazesh M. Xerostomia in the aged. Dent Clin North Am 1989;33: 75-80.
28. O'Connell AC, Baccaglini L, Fox PC, O'Connell BC, et al. Safety and efficacy of adenovirus-mediated transfer of the human aquaporin-1 cDNA to irradiated parotid glands of non-human primates. Cancer Gene Ther 1999;6:505-13.
29. Ono M, Takamura E, Shinozaki K, Tsumura T, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004;138:6-17.
30. Plemons JM, Benton E. Oral manifestations of HIV infection. Tex Dent J 2002;119:508-18.
31. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:28-46.
32. Prause JU. Frost-Larsen K, Hoj L, Isager H, et al. Lacrimal and salivary secretion in Sjogren's syndrome: the effect of systemic treatment with bromhexine. Acta Ophthalmol (Copenh) 1984;62:489-97.
33. Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson's disease. Mov Disord 2005;20:204-7.
34. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.
35. Rehman HU. Sjogren's syndrome. Yonsei Med J 2003;44:947-54.
36. Reiß M, Reiß G. Hals-Nasen-Ohrenheilkunde. Eehrbuch für Pflegeberufe. Stuttgart - Berlin - Köln: Kohlhammer, 2003.
37. Rieger J, Seikaly H, Jha N, Harris J, et al. Submandibular gland transfer for prevention of xerostomia after radiation therapy: swallowing outcomes. Arch Otolaryngol Head Neck Surg 2005;131:140-5.
38. Schiodt M, Oxholm P, Jacobsen A. Treatment of xerostomia in patients with primary Sjogren's syndrome with sulfarlem. Scand J Rheumatol Suppl 1986;61:250-2.
39. Seifert G, Miehlke A, Haubrich J, Chilla R. Speicheldrü senkrankheiten. Pathologie - Klinik - Therapie - Fazialischirurgie. Stuttgart - New York: Thieme. 1984.
40. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002;50:535-43.
41. Solans R, Bosch JA, Selva A, Simeon CP, et al. Pilocarpina oral en el tratamiento de la xerostomia y xeroftalmia en pacientes con sindrome de Sjogren primario. Med Clin (Barc) 2004;122:253-5.
42. Spiegel JH, Zhang F, Eevin DE, Singer MI, et al. Microvascular transplantation of the rat Submandibular gland. Plast Reconstr Surg 2000;106:1326-35.
43. Spolarich AE. Managing the side effects of medications. J Dent Hyg 2000;74:57-69: quiz 71-2.
44. Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-29.
45. Vernillo AT. Diabetes mellitus: Relevance to dental treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:263-70.
46. Walls AW, Steele JG. The relationship between oral health and nutrition in older people. Mech Ageing Dev 2004;125:853-7.
47. Zelickson BD, Rogers RS 3rd. Drug reactions involving the mouth. Clin Dermatol 1986;4:98-109.